Classification of First-Episode Schizophrenia Patients and Healthy Subjects by Automated MRI Measures of Regional Brain Volume and Cortical Thickness

The University of Melbourne, Australia
PLoS ONE (Impact Factor: 3.53). 06/2011; 6(6):e21047. DOI: 10.1371/journal.pone.0021047
Source: PubMed

ABSTRACT Although structural magnetic resonance imaging (MRI) studies have repeatedly demonstrated regional brain structural abnormalities in patients with schizophrenia, relatively few MRI-based studies have attempted to distinguish between patients with first-episode schizophrenia and healthy controls.
Three-dimensional MR images were acquired from 52 (29 males, 23 females) first-episode schizophrenia patients and 40 (22 males, 18 females) healthy subjects. Multiple brain measures (regional brain volume and cortical thickness) were calculated by a fully automated procedure and were used for group comparison and classification by linear discriminant function analysis.
Schizophrenia patients showed gray matter volume reductions and cortical thinning in various brain regions predominantly in prefrontal and temporal cortices compared with controls. The classifiers obtained from 66 subjects of the first group successfully assigned 26 subjects of the second group with accuracy above 80%.
Our results showed that combinations of automated brain measures successfully differentiated first-episode schizophrenia patients from healthy controls. Such neuroimaging approaches may provide objective biological information adjunct to clinical diagnosis of early schizophrenia.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund: Multivariate Analysetechniken konnten in vielfachen Studien die Möglichkeit der Anwendung von Neurobildgebungsdaten im klinischen Alltag demonstrieren. Ziel der Arbeit: Der Beitrag fasst die aktuellen Forschungsergebnisse und klinischen Anwendungen von Neurobildgebungsdaten in der Psychiatrie zusammen. Material und Methoden: Es wird eine Literaturübersicht über aktuelle Studien gegeben. Ergebnisse: Aktuelle Forschungsergebnisse im Bereich der Depression, Schizophrenie, bipolaren Störung und demenzieller Erkrankungen legen die klinische Anwendung von Neurobildgebungsdaten zur Diagnosestellung, Differenzialdiagnose und Verlaufsprädiktion nahe. Diskussion: Bisher besteht eine heterogene Studienlage mit teilweise vielversprechenden Ergebnissen. Weitere systematische, multizentrische Untersuchungen von verschiedenen, klar definierten Patientenpopulationen sind notwendig, um letztendlich die klinische Nutzung von Bildgebungsdaten zu ermöglichen. [Background: Multiple studies successfully applied multivariate analysis to neuroimaging data demonstrating the potential utility of neuroimaging for clinical diagnostic and prognostic purposes. Objectives: Summary of the current state of research regarding the application of neuroimaging in the field of psychiatry. Material and methods: Literature review of current studies. Results: Results of current studies indicate the potential application of neuroimaging data across various diagnoses, such as depression, schizophrenia, bipolar disorder and dementia. Potential applications include disease classification, differential diagnosis and prediction of disease course. Conclusion: The results of the studies are heterogeneous although some studies report promising findings. Further multicentre studies are needed with clearly specified patient populations to systematically investigate the potential utility of neuroimaging for the clinical routine.]
    Der Nervenarzt 05/2014; DOI:10.1007/s00115-014-4022-x · 0.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: We measured duration mismatch negativity (dMMN), P3a, and reorienting negativity (RON) in subjects with at-risk mental state (ARMS), patients with first-episode or chronic schizophrenia, and healthy volunteers. The main interest was to determine if these event-related potentials provide a biomarker associated with progression to overt schizophrenia in ARMS subjects. Methods: Nineteen ARMS subjects meeting the criteria of the Comprehensive Assessment of ARMS, 38 patients with schizophrenia (19 first-episode and 19 chronic), and 19 healthy controls participated in the study. dMMN, P3a, and RON were measured with an auditory odd-ball paradigm at baseline. Results: During the follow-up period (2.2 years), 4 out of the 19 ARMS subjects transitioned to schizophrenia (Converters) while 15 did not (non-Converters). dMMN amplitudes of Converters were significantly smaller than those of non-Converters at frontal and central electrodes before onset of illness. dMMN amplitudes of non-Converters did not differ from those of healthy controls, while Converters showed significantly smaller dMMN amplitudes compared to control subjects. RON amplitudes were also reduced at frontal and central electrodes in subjects with schizophrenia, but not ARMS. Converter subjects tended to show smaller RON amplitudes compared to non-Converters. Conclusions: Our data confirm that diminished dMMN amplitudes provide a biomarker, which is present before and after the development of psychosis. In this respect, RON amplitudes may also be useful, as suggested for the first time based on longitudinal observations.
    Frontiers in Behavioral Neuroscience 05/2014; 8:172. DOI:10.3389/fnbeh.2014.00172 · 4.16 Impact Factor
  • Source

Full-text (3 Sources)

Available from
Jun 3, 2014